2025 Half Year Results

Six months ended 30 June

• Group revenue up 3% organically and ahead of global IP² of 2.5% (IP excluding China: 1.7%)
• STS³ sales in line with H1 2024 organically and up 3% excluding large projects in China and Korea
• ETS³ sales up 10% organically driven by further operational progress and improved Semicon⁵ demand
• WMFTS³ sales up 2% organically; over 10% Biopharm⁵ orders growth to drive higher H2 sales growth
• Group adjusted operating profit up 7% organically; margin of 19.3% up 70bps organically
• Statutory profit and margin of 13.0% impacted by one-off restructuring costs and currency headwinds
• Currency headwinds to revenue (3%) and adjusted operating profit (7%), as expected
• Improved adjusted cash conversion of 61% reflects capital discipline and working capital efficiency
• Interim dividend up 3% to 48.9 pence

Nimesh Patel, Group Chief Executive Officer, commenting on the results said:

"We have delivered first half results in line with expectations despite the challenging macroeconomic environment, demonstrating the strength of the Group’s direct sales Business Model. Our focus on driving demand in MRO and solution-sales across STS and WMFTS Process Industries, together with increased manufacturing throughput in ETS, delivered organic sales growth ahead of IP.

“While IP forecasts have been revised down for the remainder of the year, our unchanged full year guidance is supported by strong order books going into the second half, increasing demand from key end markets, and ongoing delivery of operational priorities.

“Colleagues across the Group have successfully stepped up focus on the drivers of growth within our control as we implement our Together for Growth Strategy at pace. Our significant operational efficiency and simplification programme is funding investment in future drivers of accelerated and sustained longer term growth, including digital and decarbonisation, whilst also underpinning our confidence in delivering our medium-term targets."

¹ ‘Sales’ is used interchangeably with ‘revenue’ when describing the financial performance of the Group

² ‘IP’: Industrial Production growth

³ ‘STS’: Steam Thermal Solutions; ‘ETS’: Electric Thermal Solutions; ‘WMFTS’: Watson-Marlow Fluid Technology Solutions

⁴ Organic measures are at constant currency and exclude contributions from acquisitions and disposals

⁵ ‘Biopharm’: Pharmaceutical & Biotechnology customers; ‘Semicon’: Wafer Fabrication Equipment manufacturers

⁶ See Appendix to the Financial Statements for an explanation of alternative performance measures and reconciliation to IFRS

For further information, please contact:

Louisa Burdett, Chief Financial Officer: +44 (0) 1242 240281

Mal Patel, Head of Investor Relations: +44 (0) 1242 240281

Media

Martin Robinson, Teneo: +44 (0) 20 7260 2700

spiraxgroup@teneo.com

Audiocast

The results presentation and recording are available on the Company’s website at https://www.spiraxgroup.com/en/investors/results-reports-and-presentations or via the following link: https://edge.media-server.com/mmc/p/bzjsi944/

About Spirax Group plc

Spirax Group is positioned to play a critical role in enabling the industrial transition to net zero, aligned to our Purpose to create sustainable value for all our stakeholders as we engineer a more efficient, safer and sustainable world. We put solving customers’ problems at the heart of our total solutions approach. Our global thermal energy and fluid technology solutions improve operating efficiency and safety in our customers’ critical industrial processes. Our new-to-world decarbonisation* solutions will use our proprietary technologies to electrify boilers, for the raising of steam, as well as the electrification of other critical industrial process heating applications.

Spirax Group comprises three strong and aligned Businesses: Steam Thermal Solutions helps customers control and manage steam within their mission critical industrial applications, such as cleaning, sterilising, cooking and heating. We are helping to put food safely on the world’s tables and keeping our hospitals running. Electric Thermal Solutions has proprietary technologies that deliver electrification solutions at scale in industrial settings, including for the raising of steam, supporting our customers to achieve their net zero goals. We also deliver freeze protection and defrost solutions critical to aviation and space industries and ensure thermal uniformity in Semiconductor chip manufacturing to power the critical electronic systems we rely on. Watson‐Marlow Fluid Technology Solutions is engineering vital fluid technology solutions that optimise the efficient use of resources and support advancements in global health, such as lifesaving vaccines and gene therapies.

Spirax Group is headquartered in Cheltenham (UK). We have over 30 strategically located manufacturing plants around the world and are committed to creating a safe and inclusive working culture for our 10,000 colleagues, operating in nearly 70 countries and serving over 100,000 customers globally.

The Company’s shares have been listed on the London Stock Exchange since 1959 (symbol: SPX) and we are a constituent of the FTSE 100 and the FTSE4Good Indexes.

* Eliminates Scopes 1 and 2 greenhouse gas emissions when connected to a green electricity source.

Further information can be found at spiraxgroup.com